First, even though this is the largest global prospective clinical trial evaluating a TKI for SDH-deficient GIST, it was an open-label, single-arm, phase 1b study, which is consistent with the rarity of SDH-deficient- GIST. This evidence concerns the gene SDHB and gastrointestinal stromal tumor.